Therapy with stem cells in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 5, 2014, Pages 1211-1227

  Martínez Montiel, María del Pilar ^a   Gómez Gómez, Gonzalo Jesús ^a   Flores, Ana Isabel ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Universidad Complutense   (Spain)

Author keywords

Crohn's disease; Haematopoietic stem cell transplantation; Inflammatory bowel disease; Mesenchymal stem cell; Ulcerative colitis

Indexed keywords

CYCLOPHOSPHAMIDE; FIBRIN GLUE; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO;

ADIPOSE DERIVED STEM CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; CROHN DISEASE; DIARRHEA; FEVER; FLUSHING; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INSOMNIA; INTESTINE FISTULA; INTESTINE FLORA; MESENCHYMAL STEM CELL; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION; ULCERATIVE COLITIS;

CROHN'S DISEASE; HAEMATOPOIETIC STEM CELL TRANSPLANTATION; INFLAMMATORY BOWEL DISEASE; MESENCHYMAL STEM CELL; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTESTINES; MESENCHYMAL STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84893059046     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i5.1211     Document Type: Article

References (162)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-1794 [PMID: 21530745 DOI:10.1053/j.gastro.2011.01.055]
2. Burisch J., Pedersen N, Cukovic-Cavka S, Brinar M, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup JF, Salupere R, Nielsen KR, Olsen J, Manninen P, Collin P, Tsianos EV, Katsanos KH, Ladefoged K, Lakatos L, Björnsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D'Incà R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros LF, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos PL, Langholz E, Munkholm P; For the EpiCom-group. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2013 Apr 20; Epub ahead of print [PMID: 23604131]
3. Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-3182 [PMID: 19086963 DOI: 10.1111/j.1572-0241.2008.02158.x]
4. Wilson B., Greco M, Hommes DW, Vermiere S, Bell C. A European Crohn's and ulcerative colitis patient life IMPACT survey. Abstract PO875, 19 the United European Gastroenterology Week; 2011 October 22-26; Stockholm, Sweden
5. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis 2012; 6 Suppl 2: S224-S234 [PMID: 22463929 DOI: 10.1016/S1873-9946(12)60502-9]
6. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135: 1907-1913 [PMID: 18854185 DOI: 10.1053/j.gastro.2008.09.012]
7. Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, Maclean R. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008; 50: 1261-1272 [PMID: 19001952 DOI: 10.1097/JOM.0b013e318181b8ca]
8. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667-671 [PMID: 10536324 DOI:10.1016/S0016-5107]
9. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]
10. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn' s disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-1111. e2 [PMID: 22326435 DOI: 10.1053/j.gastro.2012.01.035]
11. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65 [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041]
12. Baert F., Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-468; quiz e10-1 [PMID: 19818785 DOI: 10.1053/j.gastro.2009.09.056]
13. Frøslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422 [PMID: 17681162 DOI: 10.1053/j.gastro.2007.05.051]
14. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201 [PMID: 21723220 DOI: 10.1053/j.gastro.2011.06.054]
15. Meucci G, Fasoli R, Saibeni S, Valpiani D, Gullotta R, Colombo E, D'Incà R, Terpin M, Lombardi G. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012; 18: 1006-1010 [PMID: 21830282 DOI: 10.1002/ibd.21838]
16. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265.e1-3 [PMID: 22062358 DOI:10.1053/j.gastro.2011.10.032]
17. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787 [PMID: 21209123 DOI:10.1136/gut.2010.221127]
18. Colombel JRP., Sandbord WJ, Camez A. Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: result s from EXTEND. Abstract OP31, 5th Congress of the European Crohn's and Colitis Organization; 2010 February 25-27; Prague, Czech Republic
19. Zalot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013; 15: 315 [PMID: 23354742 DOI: 10.1007/s11894-013-0315-7]
20. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238 [PMID: 17634458 DOI: 10.1056/NEJMoa067594]
21. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ., Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250 [PMID: 17634459 DOI:10.1056/NEJMoa062897]
22. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685-698 [PMID: 21427713 DOI: 10.1038/ajg.2011.103]
23. Bernstein CN, Loftus EV, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn's disease. Gut 2012; 61: 622-629 [PMID: 22267595 DOI: 10.1136/gutjnl-2011-301397]
24. Grant D, Abu-Elmagd K, Reyes J, Tzakis A, Langnas A, Fishbein T, Goulet O, Farmer D. 2003 report of the intestine transplant registry: a new era has dawned. Ann Surg 2005; 241: 607-613 [PMID: 15798462 DOI: 10.1097/01. sla.0000157265.85388.a1]
25. Harpaz N, Schiano T, Ruf AE, Shukla D, Tao Y, Fishbein TM, Sauter BV, Gondolesi GE. Early and frequent histological recurrence of Crohn's disease in small intestinal allografts. Transplantation 2005; 80: 1667-1670 [PMID: 16378058 DOI: 10.1097/01.tp.0000184621.63238.ec]
26. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected by Crohn' s disease. Surgery 1997; 122: 661-667; discussion 667-668 [PMID: 9347840 DOI: 10.1016/S0039-6060(97)90071-4]
27. Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg 2005; 241: 796-801; discussion 801-802 [PMID: 15849515 DOI: 10.1097/01.sla.0000161030.25860.c1]
28. Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 2012; 143: 1207-1217.e1-2 [PMID: 22885333 DOI: 10.1053/j.gastro.2012.07.116]
29. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008; 67 Suppl 3: iii90-iii96 [PMID: 19022823 DOI: 10.1136/ard.2008.099176]
30. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide metaanalysis increases to 71 the number of confirmed Crohn' s disease susceptibility loci. Nat Genet 2010; 42: 1118-1125 [PMID: 21102463 DOI: 10.1038/ng.717]
31. Fiocchi C. Genes and 'in-vironment': how will our concepts on the pathophysiology of inflammatory bowel disease develop in the future? Dig Dis 2012; 30 Suppl 3: 2-11 [PMID: 23295686 DOI: 10.1159/000342585]
32. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1720-1728 [PMID: 21530738 DOI: 10.1053/j.gastro.2011.01.054]
33. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011; 140: 1768-1775 [PMID: 21530743 DOI: 10.1053/j.gastro.2011.02.047]
34. Blumberg R, Cho J, Lewis J, Wu G. Inflammatory bowel disease: an update on the fundamental biology and clinical management. Gastroenterology 2011; 140: 1701-1703 [PMID: 21530735 DOI: 10.1053/j.gastro.2011.03.013]
35. Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006; 169: 1901-1909 [PMID: 17148655 DOI: 10.2353/ajpath.2006.060681]
36. Rimoldi M, Chieppa M, Salucci V, Avogadri F, Sonzogni A, Sampietro GM, Nespoli A, Viale G, Allavena P, Rescigno M. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005; 6: 507-514 [PMID: 15821737 DOI: 10.1038/ni1192]
37. Iliev ID, Mileti E, Matteoli G, Chieppa M, Rescigno M. Intestinal epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic cell conditioning. Mucosal Immunol 2009; 2: 340-350 [PMID: 19387433 DOI: 10.1038/mi.2009.13]
38. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078 [PMID: 19923578 DOI: 10.1056/NEJMra0804647]
39. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-241 [PMID: 15260992 DOI: 10.1016/j.cell.2004.07.002]
40. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005; 129: 50-65 [PMID: 16012934 DOI: 10.1053/j.gastro.2005.05.013]
41. Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004; 173: 3119-3130 [PMID: 15322172]
42. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006; 212: 256-271 [PMID: 16903919 DOI: 10.1111/j.0105-2896.2006.00423.x]
43. Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology 2007; 133: 1327-1339 [PMID: 17919503 DOI: 10.1053/j.gastro.2007.08.032]
44. Orholm M, Binder V, Sørensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000; 35: 1075-1081 [PMID: 11099061 DOI:10.1080/003655200451207]
45. Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2006; 12: 3668-3672 [PMID: 16773682]
46. Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993; 34: 517-524 [PMID: 8491401 DOI: 10.1136/gut.34.4.517]
47. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011; 140: 1704-1712 [PMID: 21530736 DOI: 10.1053/j.gastro.2011.02.046]
48. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, Schreiber S. Replication of signals from recent studies of Crohn' s disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40: 713-715 [PMID: 18438405 DOI: 10.1038/ng.148]
49. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, Barrett JC, Cummings FR, Drummond H, Lees CW, Onnie CM, Hanson CE, Blaszczyk K, Inouye M, Ewels P, Ravindrarajah R, Keniry A, Hunt S, Carter M, Watkins N, Ouwehand W, Lewis CM, Cardon L, Lobo A, Forbes A, Sanderson J, Jewell DP, Mansfield JC, Deloukas P, Mathew CG, Parkes M, Satsangi J. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008; 40: 710-712 [PMID: 18438406 DOI: 10.1038/ng.145]
50. Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, Gwilliam R, Jacob J, Nimmo ER, Drummond H, Lees CW, Onnie CM, Hanson C, Blaszczyk K, Ravindrarajah R, Hunt S, Varma D, Hammond N, Lewis G, Attlesey H, Watkins N, Ouwehand W, Strachan D, McArdle W, Lewis CM, Lobo A, Sanderson J, Jewell DP, Deloukas P, Mansfield JC, Mathew CG, Satsangi J, Parkes M. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 2009; 136: 523-529.e3 [PMID: 19068216 DOI: 10.1053/j.gastro.2008.10.032]
51. Brant SR, Wang MH, Rawsthorne P, Sargent M, Datta LW, Nouvet F, Shugart YY, Bernstein CN. A populationbased case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am J Gastroenterol 2007; 102: 313-323 [PMID: 17100976 DOI: 10.1111/j.1572-0241.2006.00926.x]
52. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, Khawaja SA, Bagnall R, Burke DA, Todhunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell DP, Satsangi J, Mansfield JC, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39: 830-832 [PMID: 17554261 DOI: 10.1038/ng2061]
53. Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 2011; 106: 699-712 [PMID: 21343918 DOI: 10.1038/ajg.2011.19]
54. Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, Lacy AM, Pique JM, Yagüe J, Panés J. Crohn' s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005; 242: 693-700 [PMID: 16244543]
55. Fiedler T, Büning C, Reuter W, Pitre G, Gentz E, Schmidt HH, Büttner J, Ockenga J, Gerloff T, Meisel C, Lochs H, Roots I, Köpke K, Johne A. Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. Eur J Clin Pharmacol 2007; 63: 917-925 [PMID: 17665184]
56. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612-1619 [PMID: 19700435 DOI: 10.1136/gut.2009.178665]
57. Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 2006; 12: 3636-3644 [PMID: 16773678]
58. Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, Chatterjee N. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010; 42: 570-575 [PMID: 20562874 DOI: 10.1038/ng.610]
59. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-2045 [PMID: 19890111 DOI:10.1056/NEJMoa0907206]
60. Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 2011; 140: 1713-1719 [PMID: 21530737 DOI: 10.1053/j.gastro.2011.02.011]
61. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D' Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H, Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124 [PMID: 23128233]
62. Bhatt AS, Freeman SS, Herrera AF, Pedamallu CS, Gevers D, Duke F, Jung J, Michaud M, Walker BJ, Young S, Earl AM, Kostic AD, Ojesina AI, Hasserjian R, Ballen KK, Chen YB, Hobbs G, Antin JH, Soiffer RJ, Baden LR, Garrett WS, Hornick JL, Marty FM, Meyerson M. Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med 2013; 369: 517-528 [PMID: 23924002]
63. Frolkis A, Dieleman LA, Barkema H, Panaccione R, Ghosh S, Fedorak RN, Madsen K, Kaplan GG. Environment and the inflammatory bowel diseases. Can J Gastroenterol 2013; 27: e18-e24 [PMID: 23516681]
64. Christophi GP, Rong R, Holtzapple PG, Massa PT, Landas SK. Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2012; 18: 2342-2356 [PMID: 22467146 DOI: 10.1002/ibd.22957]
65. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767 [PMID: 21530742 DOI: 10.1053/j.gastro.2011.02.016]
66. Smith A. Glossary a glossary for stem-cell biology. Nature 2006; 441: 1060 [DOI: 10.1038/nature04954]
67. Egashira T, Yuasa S, Fukuda K. Novel insights into disease modeling using induced pluripotent stem cells. Biol Pharm Bull 2013; 36: 182-188 [PMID: 23370349 DOI: 10.1248/bpb. b12-00960]
68. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471: 225-229 [PMID: 21240260 DOI: 10.1038/nature09747]
69. Swenson E, Theise N. Stem cell therapeutics: potential in the treatment of inflammatory bowel disease. Clin Exp Gastroenterol 2010; 3: 1-10 [PMID: 21694840]
70. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 2007; 1: 635-645 [PMID: 18371405 DOI: 10.1016/j.stem.2007.10.001]
71. Ikera S. Treatment of autoimmune diseases by haematopoietic stem cell transplantation. Exp Hematol 2001; 29: 661-669 [DOI: 10.1016/S0301-472X(01)00645-2]
72. van Bekkum DW. Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004; 17: 201-222 [PMID: 15302335]
73. Gratwohl A, Passweg J, Gerber I, Tyndall A. Stem cell transplantation for autoimmune diseases. Best Pract Res Clin Haematol 2001; 14: 755-776 [PMID: 11924920 DOI: 10.1053/beha.2001.0171]
74. Marmont AM. Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 2004; 17: 223-232 [PMID: 15302336 DOI: 10.1016/j.beha.2004.04.004]
75. Tyndall A, Gratwohl A. Adult stem cell transplantation in autoimmune disease. Curr Opin Hematol 2009; 16: 285-291 [PMID: 19465851 DOI: 10.1097/MOH.0b013e32832aacb3]
76. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program 2011; 2011: 280-284 [PMID: 22160046 DOI:10.1182/asheducation-2011.1.280]
77. Leung Y, Geddes M, Storek J, Panaccione R, Beck PL. Hematopoietic cell transplantation for Crohn's disease; is it time? World J Gastroenterol 2006; 12: 6665-6673 [PMID: 17075981]
78. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, Campbell C, Memon S, Nagle JW, Hakim FT, Gress RE, McFarland HF, Burt RK, Martin R. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-816 [PMID: 15738052 DOI:10.1084/jem.20041679]
79. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, Mei H, Radtke H, Gromnica-Ihle E, Burmester GR, Arnold R, Radbruch A, Hiepe F. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 214-223 [PMID: 18824594 DOI: 10.1182/blood-2008-07-168286]
80. Clerici M, Cassinotti A, Onida F, Trabattoni D, Annaloro C, Della Volpe A, Rainone V, Lissoni F, Duca P, Sampietro G, Fociani P, Vago G, Foschi D, Ardizzone S, Deliliers GL, Porro GB. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis 2011; 43: 946-952 [PMID: 21907652 DOI:10.1016/j.dld.2011.07.021]
81. García-Bosch O, Ricart E, Panés J. Review article: stem cell therapies for inflammatory bowel disease efficacy and safety. Aliment Pharmacol Ther 2010; 32: 939-952 [PMID: 20804451 DOI: 10.1111/j.1365-2036.2010.04439.x]
82. van Deen WK, Oikonomopoulos A, Hommes DW. Stem cell therapy in inflammatory bowel disease: which, when and how? Curr Opin Gastroenterol 2013; 29: 384-390 [PMID: 23666365 DOI: 10.1097/MOG.0b013e328361f763]
83. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant 1997; 19: 643-645 [PMID: 9156239]
84. Oyama Y, Craig RM, Traynor AE, Quigley K, Statkute L, Halverson A, Brush M, Verda L, Kowalska B, Krosnjar N, Kletzel M, Whitington PF, Burt RK. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005; 128: 552-563 [PMID: 15765390 DOI: 10.1053/j.gastro.2004.11.051]
85. Cassinotti A, Annaloro C, Ardizzone S, Onida F, Della Volpe A, Clerici M, Usardi P, Greco S, Maconi G, Porro GB, Deliliers GL. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn' s disease. Gut 2008; 57: 211-217 [PMID: 17895357 DOI:10.1136/gut.2007.128694]
86. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, Denton C, Hawkey C, Labopin M, Mancardi G, Martin R, Moore JJ, Passweg J, Peters C, Rabusin M, Rovira M, van Laar JM, Farge D. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 770-790 [PMID: 22002489 DOI: 10.1038/bmt.2011.185]
87. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kötter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95: 284-292 [PMID: 19773265 DOI: 10.3324/haematol.2009.013458]
88. Drakos PE, Nagler A, Or R. Case of Crohn's disease in bone marrow transplantation. Am J Hematol 1993; 43: 157-158 [PMID: 8342550 DOI: 10.1002/ajh.2830430223]
89. Castro J, Bentch HL, Smith L, Kalter S, Bachier C. Prolonged clinical remission in patients with inflammatory bowel disease after high dose chemotherapy and autologous blood stem cell transplantation. Blood 1996; 88: 133a
90. Kashyap A, Forman SJ. Autologous bone marrow transplantation for non-Hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease. Br J Haematol 1998; 103: 651-652 [PMID: 9858212 DOI: 10.1046/j.1365-2141.1998.01059.x]
91. Musso M, Porretto F, Crescimanno A, Bondì F, Polizzi V, Scalone R. Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant. Bone Marrow Transplant 2000; 26: 921-923 [PMID: 11081397 DOI: 10.1038/sj.bmt.1702621]
92. Söderholm JD, Malm C, Juliusson G, Sjödahl R. Long-term endoscopic remission of crohn disease after autologous stem cell transplantation for acute myeloid leukaemia. Scand J Gastroenterol 2002; 37: 613-616 [PMID: 12059066 DOI:10.1080/00365520252903198]
93. Craig RM, Traynor A, Oyama Y, Burt RK. Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplant 2003; 32 Suppl 1: S57-S59 [PMID: 12931244 DOI: 10.1038/sj.bmt.1703945]
94. Burt RK, Craig RM, Milanetti F, Quigley K, Gozdziak P, Bucha J, Testori A, Halverson A, Verda L, de Villiers WJ, Jovanovic B, Oyama Y. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010; 116: 6123-6132 [PMID: 20837778 DOI: 10.1182/blood-2010-06-292391]
95. Cassionotti A, Onida F, Annaloro C, Samprieto G, Fociani P, Fichera M, Maconi G, Lombardini M, Bezzio C, Foschi D, Lambertenghi Deliliers G, Bianchi Porro G, De Franchis R, Ardizzone S. Autologous hematopoietic stem cell transplantation without CD34 selection for refractory Crohn's disease: the Milan experience after 5 year. J Cronhs Colitis 2012; 6: S153 [DOI: 10.1016/S1873-9946(12)60381-X]
96. Hasselblatt P, Drognitz K, Potthoff K, Bertz H, Kruis W, Schmidt C, Stallmach A, Schmitt-Graeff A, Finke J, Kreisel W. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther 2012; 36: 725-735 [PMID: 22937722 DOI: 10.1111/apt.12032]
97. Hawkey C, Allez M, Ardizzone S, Clark M, Clark L, Colombel JF, Danese S, Farge-Bancel D, Labopin M, Lindsay J, Norman A, Onida F, Ricart E, Rogler G, Rovira M, Russel N, Satsangi J, Travis S, Tyndall A, Vermeire S. Clinical and endoscopic improvement following hemopoietic stem cell transplantation in the ASTIC trial. J Crohns Colitis 2013; 7: S4 [DOI: 10.1016/S1873-9946(13)60010-0]
98. Ditschkowski M, Einsele H, Schwerdtfeger R, Bunjes D, Trenschel R, Beelen DW, Elmaagacli AH. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 2003; 75: 1745-1747 [PMID: 12777867 DOI: 10.1097/01.TP.0000062540.29757.E9]
99. Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998; 114: 433-440 [PMID: 9496932 DOI:10.1016/S0016-5085(98)70525-6]
100. Talbot DC, Montes A, Teh WL, Nandi A, Powles RL. Remission of Crohn's disease following allogeneic bone marrow transplant for acute leukaemia. Hosp Med 1998; 59: 580-581 [PMID: 9798551]
101. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA, Ruadkow IA. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974; 2: 83-92 [PMID: 4455512]
102. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905]
103. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119: 2204-2213 [PMID: 16684817 DOI: 10.1242/jcs.02932]
104. Lanzoni G, Roda G, Belluzzi A, Roda E, Bagnara GP. Inflammatory bowel disease: Moving toward a stem cellbased therapy. World J Gastroenterol 2008; 14: 4616-4626 [PMID: 18698675 DOI: 10.3748/wjg.14.4616]
105. Macias MI, Grande J, Moreno A, Domínguez I, Bornstein R, Flores AI. Isolation and characterization of true mesenchymal stem cells derived from human term decidua capable of multilineage differentiation into all 3 embryonic layers. Am J Obstet Gynecol 2010; 203: 495.e9-495.e23 [PMID: 20692642 DOI: 10.1016/j.ajog.2010.06.045]
106. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, Taureau C, Cousin B, Abbal M, Laharrague P, Penicaud L, Casteilla L, Blancher A. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005; 129: 118-129 [PMID: 15801964 DOI: 10.1111/j.1365-2141.2005.05409.x]
107. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010; 264: 171-179 [PMID: 20619400 DOI: 10.1016/j.cellimm.2010.06.006]
108. Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, Lee JE, Kim YJ, Yang SK, Jung HL, Sung KW, Kim CW, Koo HH. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 2009; 259: 150-156 [PMID: 19608159 DOI: 10.1016/j.cellimm.2009.06.010]
109. Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2013; 2: 455-463 [PMID: 23694810 DOI: 10.5966/sctm.2012-0184]
110. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506 [PMID: 17664353 DOI: 10.1182/blood-2007-02-069716]
111. Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F, Sharma M, Sharma P, Tripathi RP, Gurudutta GU. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med 2009; 13: 4385-4402 [PMID: 19602034 DOI: 10.1111/j.1582-4934.2009.00857.x]
112. Voswinkel J, Francois S, Gorin NC, Chapel A. Gastrointestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells. Immunol Res 2013; 56: 241-248 [PMID: 23564182 DOI: 10.1007/s12026-013-8397-8]
113. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48 [PMID: 11823036 DOI: 10.1016/S0301-472X(01)00769-X]
114. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755-1761 [PMID: 15905186 DOI: 10.1182/blood-2005-04-1496]
115. Dalal J, Gandy K, Domen J. Role of mesenchymal stem cell therapy in Crohn's disease. Pediatr Res 2012; 71: 445-451 [PMID: 22430380 DOI: 10.1038/pr.2011.56]
116. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 2013; 91: 19-26 [PMID: 23090487 DOI: 10.1038/icb.2012.56]
117. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150 [PMID: 18371435 DOI: 10.1016/j.stem.2007.11.014]
118. Duijvestein M, Wildenberg ME, Welling MM, Hennink S, Molendijk I, van Zuylen VL, Bosse T, Vos AC, de JongeMuller ES, Roelofs H, van der Weerd L, Verspaget HW, Fibbe WE, te Velde AA, van den Brink GR, Hommes DW. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011; 29: 1549-1558 [PMID: 21898680 DOI:10.1002/stem.698]
119. Voswinkel J, Francois S, Simon JM, Benderitter M, Gorin NC, Mohty M, Fouillard L, Chapel A. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. Clin Rev Allergy Immunol 2013; 45: 180-192 [PMID: 23296948 DOI: 10.1007/s12016-012-8347-6]
120. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160 [PMID: 19210524 DOI: 10.1111/j.1365-2249.2009.03874.x]
121. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583 [PMID: 19398717 DOI: 10.1182/blood-2009-02-203943]
122. Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S, Le AD. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183: 7787-7798 [PMID: 19923445 DOI:10.4049/jimmunol.0902318]
123. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372 [PMID: 16141348 DOI:10.1182/blood-2005-07-2657]
124. De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12: 574-591 [PMID: 22515979 DOI: 10.2174/156652412800619950]
125. Dazzi F, Lopes L, Weng L. Mesenchymal stromal cells: a key player in 'innate tolerance'? Immunology 2012; 137: 206-213 [PMID: 22804624 DOI: 10.1111/j.1365-2567.2012.03621.x]
126. Nemoto Y, Kanai T, Takahara M, Oshima S, Nakamura T, Okamoto R, Tsuchiya K, Watanabe M. Bone marrowmesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4 memory T cells. Gut 2013; 62: 1142-1152 [PMID: 23144054 DOI: 10.1136/gutjnl-2012-302029]
127. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16: 203-209 [PMID: 20335067 DOI: 10.1016/j.molmed.2010.02.005]
128. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010; 12: 87-117 [PMID: 20415588 DOI: 10.1146/annurev-bioeng-070909-105309]
129. Burdon TJ, Paul A, Noiseux N, Prakash S, Shum-Tim D. Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential. Bone Marrow Res 2011; 2011: 207326 [PMID: 22046556 DOI: 10.1155/2011/207326]
130. Kong P, Xie X, Li F, Liu Y, Lu Y. Placenta mesenchymal stem cell accelerates wound healing by enhancing angiogenesis in diabetic Goto-Kakizaki (GK) rats. Biochem Biophys Res Commun 2013; 438: 410-419 [PMID: 23899518 DOI: 10.1016/j.bbrc.2013.07.088]
131. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML. Mesenchymal stem cellderived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008; 47: 1634-1643 [PMID: 18395843 DOI: 10.1002/hep.22236]
132. Burchfield JS, Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 2008; 1: 4 [PMID: 19014650 DOI: 10.1186/1755-1536-1-4]
133. Qi Y, Jiang D, Sindrilaru A, Stegemann A, Schatz S, Treiber N, Rojewski M, Schrezenmeier H, Vander Beken S, Wlaschek M, Böhm M, Seitz A, Scholz N, Dürselen L, Brinckmann J, Ignatius A, Scharffetter-Kochanek K. TSG-6 Released from Intradermally Injected Mesenchymal Stem Cells Accelerates Wound Healing and Reduces Tissue Fibrosis in Murine Full-Thickness Skin Wounds. J Invest Dermatol 2014; 134: 526-537 [PMID: 23921952 DOI: 10.1038/jid.2013.328.]
134. Chen QQ, Yan L, Wang CZ, Wang WH, Shi H, Su BB, Zeng QH, Du HT, Wan J. Mesenchymal stem cells alleviate TNBSinduced colitis by modulating inflammatory and autoimmune responses. World J Gastroenterol 2013; 19: 4702-4717 [PMID: 23922467 DOI: 10.3748/wjg.v19.i29.4702]
135. Sémont A, Demarquay C, Bessout R, Durand C, Benderitter M, Mathieu N. Mesenchymal stem cell therapy stimulates endogenous host progenitor cells to improve colonic epithelial regeneration. PLoS One 2013; 8: e70170 [PMID: 23922953 DOI: 10.1371/journal.pone.0070170]
136. Manuguerra-Gagné R, Boulos PR, Ammar A, Leblond FA, Krosl G, Pichette V, Lesk MR, Roy DC. Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment. Stem Cells 2013; 31: 1136-1148 [PMID: 23495088 DOI: 10.1002/stem.1364]
137. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169: 12-20 [PMID: 11340257 DOI: 10.1159/000047856]
138. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001 [PMID: 12480709 DOI:10.1182/blood-2002-06-1830]
139. Hoogduijn MJ, Crop MJ, Korevaar SS, Peeters AM, Eijken M, Maat LP, Balk AH, Weimar W, Baan CC. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation 2008; 86: 1283-1291 [PMID: 19005411 DOI: 10.1097/TP.0b013e31818aa536]
140. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441 [PMID: 15121408 DOI: 10.1016/S0140-6736(04)16104-7]
141. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graftversus-host disease. Biol Blood Marrow Transplant 2009; 15: 804-811 [PMID: 19539211 DOI: 10.1016/j.bbmt.2008.03.012]
142. Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, Herrmann RP, Kebriaei P. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter Phase III trial in GVHD. Biol Blood Marrow Tr 2010; 16: S169-70 [DOI: 10.1016/j.bbmt.2009.12.057]
143. Bornstein R, Macias MI, de la Torre P, Grande J, Flores AI. Human decidua-derived mesenchymal stromal cells differentiate into hepatic-like cells and form functional threedimensional structures. Cytotherapy 2012; 14: 1182-1192 [PMID: 22900961 DOI: 10.3109/14653249.2012.706706]
144. Vegh I, Grau M, Gracia M, Grande J, de la Torre P, Flores AI. Decidua mesenchymal stem cells migrated toward mammary tumors in vitro and in vivo affecting tumor growth and tumor development. Cancer Gene Ther 2013; 20: 8-16 [PMID: 23037810 DOI: 10.1038/cgt.2012.71]
145. Onken J, Gallup D, Hanson J, Pandak M, Custer L. Sucessful outpatient treatment of refractory Cron's disease using adult mesenchymal stem cells. American College of Gastroenterology Annual Meeting; 2006; Las Vegas. Available from: URL: http://www.acgmeuniverse.org Accessed July 2, 2011
146. Osiris Therapeutics. A phase III, multicenter, placebocontrolled, randomized, double-blind study to evaluate the safety and efficacy of Prochimal [tm] (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion for induction of remission in subjects experiencing treatmentrefractory moderate-to-severe Crohn's disease. Clinical Trials. Gov 2010, NCTO0482092 Available from: URL: http://www.Clinicaltrials.gov/ct2/show/NCT00482092
147. Mannon PJ. Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn's disease. Expert Opin Biol Ther 2011; 11: 1249-1256 [PMID: 21787241 DOI:10.1517/14712598.2011.602967]
148. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59: 1662-1669 [PMID: 20921206 DOI: 10.1136/gut.2010.215152]
149. Liang J, Zhang H, Wang D, Feng X, Wang H, Hua B, Liu B, Sun L. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut 2012; 61: 468-469 [PMID: 21617158 DOI: 10.1136/gutjnl-2011-300083]
150. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012; 7: e47559 [PMID: 23133515 DOI: 10.1371/journal. pone.0047559]
151. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262: 509-525 [PMID: 17949362 DOI: 10.1111/j.1365-2796.2007.01844. x]
152. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397 [PMID: 16732175 DOI: 10.1097/01.tp.0000214462.63943.14]
153. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F, Dionigi P, Perotti C, Locatelli F, Corazza GR. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60: 788-798 [PMID: 21257987 DOI: 10.1136/gut.2010.214841]
154. Ahrendt M, Hammerschmidt SI, Pabst O, Pabst R, Bode U. Stromal cells confer lymph node-specific properties by shaping a unique microenvironment influencing local immune responses. J Immunol 2008; 181: 1898-1907 [PMID: 18641327]
155. García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, García-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis 2003; 18: 451-454 [PMID: 12756590 DOI: 10.1007/s00384-003-0490-3]
156. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-228 [PMID: 11304456 DOI:10.1089/107632701300062859]
157. García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48: 1416-1423 [PMID: 15933795 DOI: 10.1007/s10350-005-0052-6]
158. Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009; 52: 79-86 [PMID: 19273960 DOI:10.1007/DCR.0b013e3181973487]
159. Herreros MD, Garcia-Arranz M, Guadalajara H, De-LaQuintana P, Garcia-Olmo D. Autologous expanded adiposederived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and longterm evaluation. Dis Colon Rectum 2012; 55: 762-772 [PMID: 22706128 DOI: 10.1097/DCR.0b013e318255364a]
160. de la Portilla F, Alba F, García-Olmo D, Herrerías JM, González FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 2013; 28: 313-323 [PMID: 23053677 DOI: 10.1007/s00384-012-1581-9]
161. García-Olmo D, Herreros D, De-La-Quintana P, Guadalajara H, Trébol J, Georgiev-Hristov T, García-Arranz M. Adipose-derived stem cells in Crohn's rectovaginal fistula. Case Rep Med 2010; 2010: 961758 [PMID: 20224798 DOI:10.1155/2010/961758]
162. Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis 2012; 27: 595-600 [PMID: 22065114 DOI: 10.1007/s00384-011-1350-1]